A randomized, controlled, safety study using imiquimod for the topical treatment of anogenital warts in HIV-infected patients

AIDS

Volumn 13, Issue 17, 1999, Pages 2397-2404

  Gilson, Richard J C ^a,h   Shupack, Jerome L ^a,b   Friedman Kien, Alvin E ^a,b,c   Conant, Marcus A ^a,b,c,d   Weber, Jonathon N ^a,b,c,d,e   Nayagam, Andrew T ^a,b,c,d,e,f   Swann, Robert V ^{a,b,c,d,e,f,g}   Pietig, Diane C ^a,b,c,d,e   Smith, Michael H ^a,b,c,d   Owens, Mary L ^a,b,c  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^b NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^c Conant Medical Group ^*  (United States)

^d IMPERIAL COLLEGE SCHOOL OF MEDICINE   (United Kingdom)

^e ROYAL SUSSEX COUNTY HOSPITAL   (United Kingdom)

^f M Health Care   (United Kingdom)

^g 83M Pharmaceuticals   (United States)

^h UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Anogenital warts; Condylomata acuminata; HIV; HPV; Human papillomavirus; Imiquimod; Immune response modifier; Immunomodulator

Indexed keywords

ACICLOVIR; ANTIRETROVIRUS AGENT; DRUG VEHICLE; IMIQUIMOD;

ADULT; ARTICLE; CLINICAL TRIAL; CONDYLOMA; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREAM; DIARRHEA; DOUBLE BLIND PROCEDURE; FEMALE; HERPES SIMPLEX; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; PAIN; PHOTOGRAPHY; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; SKIN MANIFESTATION; T LYMPHOCYTE; TOPICAL DRUG ADMINISTRATION; UNITED KINGDOM; UNITED STATES; VIRAL SKIN DISEASE;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, TOPICAL; ADULT; AMINOQUINOLINES; CD4 LYMPHOCYTE COUNT; CONDYLOMATA ACUMINATA; DOUBLE-BLIND METHOD; DRUG ERUPTIONS; FEMALE; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; SAFETY;

EID: 0032778213     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-199912030-00011     Document Type: Article

References (27)

1. Becker TM, Stone KM, Alexander ER. Genital human papillomavirus infection. A growing concern. Obstet Cynecol Clin North Am 1987, 14:389-396.
2. Lowy DR, Kirnbauer R, Schiller JT. Genital human papillomavirus infection. Proc Nat/ Acad Sei USA 1994, 91:2436-2440.
3. McLachlin CM. Pathology of human papillomavirus in the female genital tract. Curr Opin Obstet Gynecol 1995, 7:24-29.
4. Kraus S), Stone KM. Management of genital infection caused by human papillomanvirus. Rev Infect Dis 1990, 12(Suppl. 6):S620-S632.
5. Stone KM. Human papillomavirus infection and genital warts: Update on epidemiology and treatment. Clin Infect Dis 1995, 20:S91-S97.
6. Oriel JD. Natural history of genital warts. BrJ Vener Dis 1971, 47:1-13.
7. Coleman N, Birley HDL, Renton AM, et al. Immunological events in regressing genital warts. Am ! Clin Palhol 1994, 102:768-774.
8. Bishop PE, McMillan A, Fletcher S. An immunohistological study of spontaneous regression of condylomata acuminata. Cenitourin Med 1990, 66:79-81.
9. Nakajima H, Nakao A, VVatanabe Y, et al. IFN-ct inhibits antigen-induced eosinophil and CD4+ T cell recruitment into tissue.; Immunol 1994, 153:1264-1270.
10. Arany I, Tyring SK. Status of local cellular immunity in inlerferon-responsive and nonresponsive human papillomavirusassociated lesions. Sex Transm Dis 1996, 23:475-480.
11. Arany I, Trying SK. Activation of local cell-mediated immunity in interferon-responsive patients with human papillomavirusassociated lesions. J Interferon Cylokine Res 1996, 16:453-460.
12. Gibson SJ, Imberston LM, Wagner TL, e! aJ. Cellular requirements for cytokine production in response to the immunomodulators imiquimod and 5-27609. ] Interferon Cylokine Res 1995, 15:537-545.
13. Beutner K, Tyring S, Trofatter K et al. Imiquimod, a patient applied immune-response modifier for treatment of external genital warts. Anlimicrob Agents Chemolher 1998, 42:789-794.
14. Edwards L, Ferenczy A, Eron L, ef. al. Self-administered topical 5% imiquimod cream for external anogenital warts. Arch Dermale/1998, 134:25-30.
15. Tyring SK, Arany I, Stanley MA, et al. A randomized, controlled, molecular study of condylomata acuminata clearance during treatment with imiquimod. j Infect Dis 1998, 178:551-555.
16. US Department of Health and Human Services; Center for Disease Control. 1993 Revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR 1992, 41(RR-17):1-19.
17. Wikstrom A, von Krogh G, Hedblad, MA, et al. Papillomavirusassociated balanoposthitis. Cenitourin Med 1994, 70:175-181.
18. McMillan A, Bishop PE. Clinical course of anogenital warts in men infected with human immunodeficiency virus. Cenitourin Med 1989, 65:225-228.
19. Fennema )S, van Ameijden EJ, Coutinho RA, et al. HIV, sexually transmitted diseases and gynaecologic disorder in women: increased risk for genital herpes and warts among HIVinfected prostitutes in Amsterdam. AIDS 1995, 9:1071-1078.
20. Judson FN. Interactions between human papillomavirus and human immunodeficiency virus infections. IARC Sei Publ 1992, 119:199-207.
21. Knight SC, Macatonia SE. Effect of HIV on antigen presentation by dendritic cells and macrophages. Res Virol 1991, 142:123-128.
22. Ambrus JL, Poiesz BJ, Lillie MA, et al. Interferon and interferon inhibitor levels in patients infected with varicella-zoster virus, acquired immunodeficiency syndrome, acquired immunodeficiency-related complex, or Kaposi's sarcoma, and in normal individuals. Am J Med 1989, 87:405-407.
23. Hammer SM, Squires KE, Hughes MD, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. N Eng ] Med 1997, 337:725-733.
24. Aboulafia DM. Regression of acquired immunodeficiency syndrome-related pulmonary Kaposi's sarcoma after highly active antiretroviral therapy. Mayo Clin Proc 1998, 73:439-443.
25. Okamato T, Matsuyama T, Mori S, et al. Augmentation of human immunodeficiency virus type 1 gene expression by tumor necrosis faclor-a. AIDS Res Hum Retrovlruses 1989, 5:131-138.
26. Imbertson LM, Beaurline JM, Couture AM, et al. Cytokine induction in hairless mouse and rat skin after topical application of immune response modifiers imiquimod and S-28463. ; Invest Dermatql 1998, 110:734-739.
27. Goldstein D, Hertzog P, Tomkinson E, et aJ. Administration of imiquimod, an interferon inducer, in asymptomatic HIV infected persons to determine safety and biological response modification. ; Infect Dis 1998, 178:858-861.